Knight-Swift Transportation Holdings Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Knight-Swift Transportation Holdings Inc. trades at $64.4 (market cap $10.59B), while State Street SPDR S&P Biotech ETF trades at $153.81 (market cap $10.11B). The key difference: Knight-Swift Transportation Holdings Inc. and State Street SPDR S&P Biotech ETF are close in size by market cap, and Knight-Swift Transportation Holdings Inc. pays a 1.23% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Knight-Swift Transportation Holdings Inc. for 1 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| KNX | XBI | |
|---|---|---|
Market Cap | $10.59B | $10.11B |
Volume | 2,972,511 | 12,903,266 |
Sector | Industrials | Broad Market / Factor |
52-Week High | $82.45 | $169.55 |
52-Week Low | $41.68 | $104.99 |
Typical Hold Time | 1 Days | 38 Days |
Enterprise Value | $13.09B | — |
Dividend Yield | 1.23% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Trailing returns across standard periods
Knight-Swift provides truckload, less-than-truckload, logistics, and freight management services. It operates a large transportation network across North America.
Read more on KNX →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →